Cancer Control最新文献

{"title":"Moderate Hypofractionated Post-Prostatectomy Radiotherapy (MYSTERY) Versus Conventionally Fractionated Post-Prostatectomy Radiotherapy (COPORT) for the Patients With Localized Prostate Cancer: The Protocol of a Prospective, Randomized Trial.","authors":"Yiyin Liang, Weiwei Zhang, Xianzhi Zhao, Huojun Zhang","doi":"10.1177/10732748251317682","DOIUrl":"10.1177/10732748251317682","url":null,"abstract":"<p><strong>Introduction: </strong>A few studies have examined whether the safety and efficacy of moderate hypofractionated post-prostatectomy radiotherapy (moderate HYPORT, also called MYSTERY) are equal to those of conventionally fractionated post-prostatectomy radiotherapy (COPORT) in patients with localized prostate cancer. Therefore, this study aims to compare the safety and efficacy of MYSTERY and COPORT in patients with postoperative prostate cancer.</p><p><strong>Methods and analysis: </strong>This study is a prospective, single-center, open-label, randomized controlled clinical trial. Patients with localized prostate cancer will be randomly allocated to receive COPORT (66-74 Gy at 2 Gy per fraction) or MYSTERY (57.5-65 Gy at 2.5 Gy per fraction). The primary outcomes are radiotherapy-related gastrointestinal and genitourinary adverse events. Secondary outcomes include progression-free survival, quality of life, medical expenses, and overall survival.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251317682"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-Surgical Education and Discharge Planning for Head and Neck Cancer: A Qualitative Study of Patient and Caregiver Perspectives.","authors":"Ameer Basta, Marian Mikhael, Bhargav Kansara, Emma Hume, Oliver T Nguyen, Maija Reblin, Amir Alishahi Tabriz, Young-Rock Hong, Jeffery Scott Magnuson, Krupal Patel, Kea Turner","doi":"10.1177/10732748251331979","DOIUrl":"https://doi.org/10.1177/10732748251331979","url":null,"abstract":"<p><p>IntroductionResearch on pre-surgical education and discharge planning for head and neck cancer (HNC) remains limited. To address this gap, this qualitative study aims to assess patient and caregiver perspectives on pre-surgical education and discharge planning in HNC surgery.Methods and MaterialsSemi-structured interviews were conducted with 13 individuals who received HNC surgery and 10 of their caregivers after hospital discharge. Participants were recruited from an NCI-designated Comprehensive Cancer Center and a community oncology setting.ResultsFive key recommendations for HNC surgical care emerged from the data: (1) improve communication about anticipated side effects; (2) provide targeted education through multiple modalities; (3) connect patients and caregivers with individuals who have gone through HNC surgery; (4) improve patient-provider communication for individuals with speech, vision, and hearing impairment; and (5) present the best and worst case scenarios to prepare individuals for post-surgical recovery. ConclusionParticipants identified gaps in pre-surgical education and discharge planning and provided recommendations to improve HNC surgical care.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251331979"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144058289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toxicity Profile and Efficacy of Docetaxel Following Paclitaxel- or Pemetrexed-Platinum Chemotherapy Alone or in Combination With Immune Checkpoint Inhibitors in NSCLC Patients: A Single Institution Retrospective Analysis.","authors":"Blerina Resuli, Julia Walter, Diego Kauffmann-Guerrero, Pontus Mertsch, Maria Arredondo Lasso, Paola Arnold, Christian Schneider, Jürgen Behr, Amanda Tufman","doi":"10.1177/10732748251328618","DOIUrl":"https://doi.org/10.1177/10732748251328618","url":null,"abstract":"<p><p>BackgroundDocetaxel alone or in combination with ramucirumab or nintedanib is recommended as second-line treatment in metastatic non-small cell lung cancer (NSCLC) patients after progression on first-line platinum-base chemotherapy in combination with immune-checkpoint inhibitors (ICI). The purpose of our study was to compare the toxicity profile and efficacy of docetaxel after paclitaxel- or pemetrexed-platinum chemotherapy alone or in combination with ICI.Patients und MethodsMetastatic NSCLC patients treated with docetaxel after pemetrexed or paclitaxel-platinum with chemotherapy with or without ICI were included in our retrospective analysis.ResultsWe included in our analyses a total of 53 patients (median age 60.3 years (SD 9.35) in the paclitaxel-group, and 62 years (SD 12) in the pemetrexed-group) treated at our Institution with docetaxel following either paclitaxel or pemetrexed chemotherapy. No treatment-related deaths and no new safety signals were observed.ConclusionDocetaxel alone or in combination with ramucirumab or nintedanib demonstrated encouraging antitumor activity with a manageable safety profile in patients who have progressed on previous paclitaxel-or pemetrexed platinum-based chemotherapy. The results of this analysis can be a helpful reference in conducting further trials of new second-line treatment options.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251328618"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Clinical Efficacy of Liquid-Based Cytology and High-Risk Human Papillomavirus Testing With Partial Genotyping in Cervical Screening of Women Below 30 Years Old.","authors":"Joella Xiaohong Ang, Sun Kuie Tay","doi":"10.1177/10732748251336414","DOIUrl":"https://doi.org/10.1177/10732748251336414","url":null,"abstract":"<p><p>IntroductionWe evaluated the clinical efficacy of primary Human Papillomavirus (HPV) testing and liquid-based cytology (LBC) for cervical screening in women below 30 years old.MethodsThis was a retrospective analysis of data collected prospectively from women 25 years or older who attended hospital-based gynaecology clinics for cervical screening. Simultaneous high-risk HPV testing with partial genotyping and LBC testing was performed. Comparison of clinical efficacy of HPV testing and LBC was performed for routine screening discharge rate, colposcopy referral rate, and number of colposcopies needed for each CIN2+ detected.ResultsOf 6398 women included, 503 women (7.9%) tested positive for HPV DNA. The positivity was higher for 25-to-29 years old than for women ≥30 years old (12.6% vs 7.3%, <i>P</i> < .001). The rate was markedly skewed by a low rate for women ≥45 years old. Similarly, more women below 30 years old (10.6%) had abnormal LBC results compared to women ≥30 years old (6.0%). Comparing LBC and HPV testing, the observed difference was not significant for discharge rate to interval screening (89.5% vs 87.4%). A higher referral to coloscopy rate (6.6 % vs 7.8%) was observed for HPV screening but the number of colposcopies for each detected CIN2+ (5 vs 7) was not significantly different. Clinical efficacy of HPV and LBC testing was similar in comparisons of women in 5-year groupings between 25 and 44 years old.ConclusionsOur data indicated that cervical screening for women between 25 and 29 years old could adopt HPV screening as the older women.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251336414"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Intraoperative Blood Transfusions on Survival Rates in Ovarian Cancer Patients.","authors":"Steven Benyahia, Monica Avila, Emily Coughlin, Amreesh Mahil, Alejandra Riveron, Yi Luo, Robert Wenham, Jeffrey Huang","doi":"10.1177/10732748251339248","DOIUrl":"https://doi.org/10.1177/10732748251339248","url":null,"abstract":"<p><p>IntroductionOvarian cancer remains a leading cause of gynecologic cancer-related mortality worldwide. Identifying perioperative factors that influence survival outcomes is essential for optimizing care. This study evaluates the impact of perioperative factors such as intraoperative blood transfusions and hospital length of stay (LOS) on survival rates in ovarian cancer patients undergoing surgical debulking.MethodsThis retrospective study analyzed charts of 314 patients who underwent ovarian cancer surgery at a single institution between 2010 and 2018. Patients were grouped based on survival status: \"Live\" or \"Death\". Variables included demographics, tumor size, comorbidity, anesthesia time, surgery time, estimated blood loss, transfusion, readmission, hospital stay length, and survival. Statistical analyses included log-rank tests and mean survival estimations: chi-square tests and Mann-Whitney U-test. Significance was set at <i>P</i> < .05.ResultsThe mean follow-up was 50.5 months (95% CI, 47.8-53.2). Prolonged LOS (>3 days) was significantly associated with reduced survival (47.4 vs 52.4 months, <i>P</i> = .015). Patients requiring intraoperative blood transfusions had poorer survival outcomes (42.0 months 95% CI, 36.3-47.7 vs 53.1 months 95% CI, 50.3-55.9, <i>P</i> < .001). The \"Death\" group experienced greater blood loss, longer surgical/anesthesia times, and higher intraoperative fluid requirements.ConclusionProlonged hospital stays and intraoperative blood transfusions are associated with worse survival outcomes in ovarian cancer patients undergoing surgery. These findings underscore the importance of perioperative optimization strategies, including minimizing transfusion requirements and reducing LOS through enhanced recovery protocols.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251339248"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Retrospective Observational Study on the Impact of Digital Strategies to Boost Cervical Screening Uptake in Primary Care.","authors":"Lisa Haith, Carl Deaney, Danielle Reesby, Victoria Ellis, Georgia Cole, Victoria Scott, Alena Nicholson, Rachael Hemingway-Deaney","doi":"10.1177/10732748251330705","DOIUrl":"10.1177/10732748251330705","url":null,"abstract":"<p><p>IntroductionCervical cancer is largely preventable through regular screening, yet uptake in the UK remains below national targets, particularly among harder-to-reach groups. Despite national efforts, barriers such as fear, embarrassment, and low health literacy continue to hinder participation. This retrospective study evaluates the impact of delivering information and education regarding cervical screening (CS) to hard-to-reach populations, with the aim of increasing CS uptake in line with the national target of 80% coverage.MethodsUsing a multidisciplinary team approach, women who had previously missed screenings were identified through electronic records. Remote interventions, including educational videos delivered via email and SMS, and an online booking system, were implemented to provide accessible information and flexible appointment options. These interventions aimed to address common barriers and encourage informed participation.ResultsOver 3 months, screening rates increased significantly. Uptake among women aged 25-49 rose from 77% to 80.5%, while rates among women aged 50-64 improved from 81% to 97%.ConclusionThis study highlights the potential effectiveness of remote communication tools in increasing cervical screening participation, particularly among populations historically less likely to engage. Integrating digital resources into routine practice also has the potential to reduce administrative burdens, improve patient education, and make screening more accessible. By addressing key barriers and providing flexible booking options, primary care clinics can enhance screening uptake, supporting earlier cervical cancer detection and ultimately improving patient outcomes.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251330705"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12032430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Which Types of Patients With Extensive-Stage Small Cell Lung Cancer Benefit From Radiotherapy? A Retrospective Study Integrating Machine Learning With the SEER Database and a Chinese Cohort.","authors":"Haojun Wang, Huiru Zhang, Yan Yao, Yang Yu, Longyun Wang, Ruijuan Liu, Changgang Sun, Jing Zhuang","doi":"10.1177/10732748251347679","DOIUrl":"10.1177/10732748251347679","url":null,"abstract":"<p><p>IntroductionAccurate machine learning-based prognostic models for the diagnosis and treatment of extensive-stage small cell lung cancer (ES-SCLC) are currently lacking, and the role of radiotherapy in ES-SCLC remains a subject of ongoing debate.MethodsThis study used data from the Surveillance, Epidemiology, and End Results (SEER) database of patients diagnosed with ES-SCLC. Cox regression analysis was performed to identify the key prognostic factors. Six machine learning models were developed: XGBoost, support vector machine, k-nearest neighbors, random forest, Iterative Dichotomiser 3, and logistic regression. External validation was conducted using the medical records of ES-SCLC patients who met the screening criteria at a local hospital. Propensity score matching was applied to address baseline imbalance. Kaplan-Meier (K-M) survival analysis was used to evaluate the prognostic impact of radiotherapy, followed by stratified K-M analysis to further explore its applicability across subgroups.ResultsThe analysis revealed that radiotherapy, chemotherapy, and liver metastasis were significantly associated with prognosis (<i>P</i> < .001). Liver metastasis was an independent risk factor of poor survival. The stratified K-M analysis suggested that radiotherapy may benefit certain patient subgroups.ConclusionThis study provides novel insights into radiotherapy indications for ES-SCLC, contributing to improved clinical guidelines and treatment strategies based on machine learning-derived prognostic models.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251347679"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12130661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcomes of Patients Diagnosed With Sacral Chordoma in a Retrospective Multicenter Study.","authors":"Aneta Maria Borkowska, Andrzej Pieńkowski, Paulina Chmiel, Tomasz Skóra, Radosław Michalik, Piotr Rutkowski, Mateusz Jacek Spałek","doi":"10.1177/10732748251323730","DOIUrl":"10.1177/10732748251323730","url":null,"abstract":"<p><p>BackgroundChordoma is a rare and aggressive primary bone sarcoma. En-block resection remains the primary treatment, but some patients are unable to undergo it due to the location and potential complications. Currently, there is no direct comparison of the effects of radiotherapy (RTH) and surgical treatment. However, retrospective analyses indicate the potential benefits of using RTH.MethodsA retrospective analysis was conducted on 48 patients with sacral chordoma who were treated with surgery and/or radiotherapy between 2001-2020. Among those, 22 were initially treated with surgery, 19 with definitive radiotherapy, and 7 received combined treatment. The outcomes of the treatment of recurrence in 16 patients were considered. The resection margins were defined according to R classification, and the Kaplan-Meier method was employed to calculate disease-free survival (DFS) and overall survival (OS).ResultsThe median (mOS) for the entire cohort was 80.6 months (95% CI: 62.3-NA), and the median (mDFS) was 40.4 months (95% CI: 35-69.5). Patients who underwent radical surgery of the primary tumor did not achieve the mOS (mean 68), while patients treated only with RTH for the primary tumor achieved an mOS of 62.3 months (95% CI: 52.1-NA). This resulted in a significant advantage of surgery over RTH in terms of OS (<i>P</i> = 0.01). This was not observed for DFS. The 3-year DFS rates were 65% in the surgical treatment group and 53.3% in the RTH group. The 3-year OS rates were 96% in the surgery group and 88.9% in the RTH group. In the treatment of recurrence, there were no statistically significant differences between RTH and surgery, for OS (<i>P</i> = 0.76).ConclusionsRadical surgery remains the optimal treatment for sacral chordoma. For patients who are not candidates for surgical intervention, RTH offers excellent long-term outcomes. The treatment of recurrence remains a significant challenge. Comparing modern RTH techniques and surgical procedures could provide further insights.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251323730"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized Placebo-Controlled Trial of Memantine for Smoking Cessation (CCCWFU 99311).","authors":"John Spangler, Elizabeth Skidmore, Emily V Dressler, Kathryn E Weaver, Glenn J Lesser, Gary Burton, Benjamin Esparaz, Brooke Gillett, Edward G Shaw","doi":"10.1177/10732748251336416","DOIUrl":"10.1177/10732748251336416","url":null,"abstract":"<p><p>IntroductionQuitting smoking is challenging even with existing pharmacotherapy. Thus, discovery of new cessation medications is imperative. Memantine, a well-tolerated Alzheimer's disease drug, partially antagonizes glutamate at the N-methyl-D-Aspartate receptor (NMDAR), modulating dopamine release in addiction pathways. Memantine may interrupt nicotine reward and promote smoking cessation.Materials and MethodsAt 23 community oncology practices nationwide, we recruited 130 breast, prostate, lung, or colorectal cancer survivors ≥ six months beyond definitive treatment who currently smoked at least 10 cigarettes daily and wanted to quit. In a double-blind fashion, participants were randomized to take either memantine (10 mg) or a matching placebo twice daily for 12 weeks (65 per arm). Toxicity, nicotine dependence, and past-week abstinence were recorded at 2, 4-, 6-, 9-, and 12-weeks post-randomization. The primary endpoint was feasibility and preliminary estimation of 12-week self-reported past-week smoking abstinence.ResultsThere were no significant differences in abstinence rates or nicotine dependence between the two groups at 12 weeks. Twelve-week completion of therapy was low, but lower in memantine than control participants (42% vs 63%, respectively; <i>P</i> = .01). Memantine participants reported trends of less anxiety, craving, and hunger. No significant differences in toxicity were observed between groups. Serious adverse events (3 in memantine arm, 1 in control arm) occurred; none considered possibly or probably related to study medication.ConclusionMemantine did not improve 12-week smoking abstinence rates in cancer survivors. While other NMDAR antagonists might deserve evaluation, this study suggests memantine is not efficacious for smoking cessation in a cancer survivor subpopulation.Trial registration numberNCT01535040 - February 17, 2012.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251336416"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062594/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144008675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"M6A Methylation Regulators METTL3 and ALKBH5 are Risk Factors for EGFR-Mutant NSCLC.","authors":"Yaofeng Zhi, Silin Liu, Xuefei Chang, Wanxian Guan, Ronggang Li, Qiongru Liu, Jiaqing Chen, Jie Ling, Xulin Zhao, Aibin Liu, Jiarong Chen, Xin Zhang, Yanming Huang","doi":"10.1177/10732748251342685","DOIUrl":"10.1177/10732748251342685","url":null,"abstract":"<p><p>IntroductionNon-small cell lung cancer (NSCLC), which accounts for >85% of all lung cancers, is the most common solid malignant tumor, with high morbidity and mortality worldwide. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment is widely used clinically because the epidermal growth factor receptor (EGFR) is the main driver gene of lung cancer; however, the development of drug resistance is inevitable. Epigenetic abnormalities can also lead to tyrosine kinase inhibitor (TKI) resistance. However, the relationship between N6-methyladenosine (m6A)-related proteins and EGFR mutations in NSCLC and their clinical significance remain unclear. In this retrospective study, the expression of m6A-related regulatory factors in patients with EGFR mutations were analyzed to investigate their relationship with clinicopathological features and prognoses.MethodsThe association between m6A-related regulatory factors and NSCLC was analyzed using data derived from The Cancer Genome Atlas, case collection, follow-up, immunohistochemistry, and scoring.ResultsA total of 246 NSCLC specimens were examined in this study. Among these, 143 EGFR-mutant cases exhibited significantly higher expression of METTL3 and ALKBH5 compared to EGFR-wildtype specimens. The median progression-free survival time of patients with high METTL3 expression (SI >6) was 25.0 months, and that of patients with high ALKBH5 expression (SI >6) was 24.1 months in EGFR-mutant cases. High METTL3 and ALKBH5 expression levels are independent risk factors for progression-free survival in patients with EGFR mutations. The median progression-free survival time of patients with EGFR mutations was 45.7 months in those with high expression of METTL3 or ALKBH5 alone, whereas it decreased to 20.1 months in those with high simultaneous expression of METTL3 and ALKBH5.ConclusionsMETTL3 and ALKBH5 were upregulated in NSCLC tissues with EGFR mutations and significantly correlated with poor prognoses. Thus, METTL3 and ALKBH5 may serve as prognostic biomarkers in EGFR-mutant NSCLC.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251342685"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}